

Peptonic Medical AB: Anna Linton resigns as CEO

Peptonic Medical AB (publ) ("Peptonic" or the "Company") today announces that Anna Linton, at her own request, resigns from her role as Chief Executive Officer.

The Board has initiated the process of recruiting a successor. During her notice period, Anna Linton will remain in her role and continue to lead the Company in accordance with established plans, with a focus on carrying out the Company's reconstruction and international expansion.

"The Board wishes to thank Anna Linton for her contributions and dedication during her tenure as CEO," says Anders Blom, Chairman of the Board of Peptonic Medical AB.

The Company's operations continue according to plan.

For further information, please contact:

Anna Linton, CEO, Peptonic Medical AB

Email: anna.linton@peptonicmedical.se

Phone: +46 70-244 92 07

About Peptonic Medical AB

PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.

This disclosure contains information that PEPTONIC Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on August 26, 2025, 08:00 CET.